Appointment of Mr. Satyam Reddy as Additional Independent Director
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs' board, at its 08 September 2025 meeting, approved several items ahead of the 30th AGM on 30 September 2025. Mr. Satyam Reddy Gopidi was appointed as an Additional Non-Executive Independent Director for 5 years; he is not related to any existing director. Mr. S. Nagi Reddy was re-appointed as Chairman & Managing Director for 4 years (from 30.05.2026), while Mr. S. Koni Reddy (also the CFO) and Mr. S. Manoj Kumar Reddy were re-appointed as Whole-Time Directors for 5 years each. The board also approved the FY25 Annual Report, audited financial statements, book closure from 24–30 September 2025, cost auditor remuneration ratification, material related-party transactions for FY26, and the appointment of M/s PSK & Associates as Secretarial Auditor for 5 years (FY26–FY30). The board remains family-controlled, with promoter S. Nagi Reddy (28.6 lakh shares) and his two sons holding key executive roles.
This is largely a routine governance and AGM-preparation update with no major surprises; re-appointment of the promoter family in top roles and the addition of one independent director is continuity-focused and unlikely to move the stock meaningfully. Shareholders should watch the AGM voting outcome on the director re-appointments and the RPT approvals.